Healthcare / BiotechnologyASX
$0.00
-0.00 (-11.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-5.1M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
752.6%
↑Gross Margin
N/A
•Debt/Equity
-2.95
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-4.5M · FCF $-2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | — | — | $987936.00 | $848190.00 |
| Net Income | $-4.5M | $-4.5M | $-5.4M | $-4.9M | $-6.1M | — |
| EBITDA | $-4.4M | $-4.4M | $-5.2M | $-4.7M | $-5.9M | — |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | — |
| Gross Margin | — | — | — | — | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | -785.9% | — |
| Net Margin | — | — | — | — | -613.5% | — |
| Balance Sheet | ||||||
| Debt/Equity | -2.95 | -2.95 | 1.33 | 2.10 | 0.74 | — |
| Current Ratio | 0.89 | 0.89 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-2.9M | $-2.9M | $-5.3M | $-5.1M | $-4.1M | — |
| Returns | ||||||
| ROE | 752.6% | 752.6% | -265.0% | -254.0% | -112.7% | — |
| Valuation | ||||||
| P/B | — | — | 6.09 | 5.50 | 2.48 | — |
| Growth & Yield | ||||||
| Revenue Growth | — | — | — | — | 16.5% | — |
| EPS Growth | 24.6% | 24.6% | 28.3% | 30.3% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+60.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.01
Residual
+60.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.